Skip to main content
. 2015 Apr 18;15:303. doi: 10.1186/s12885-015-1309-7

Figure 3.

Figure 3

TTP (A) and PFS (B) (population of patients receiving everolimus as second-line treatment, n = 211). PFS, progression-free survival; TTP, time to progression.